Business Context and Reporting Period
Company: Inspire Medical Systems, Inc. (NYSE: INSP)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Inspire is a medical technology company focused on the development and commercialization of the Inspire system, a minimally invasive, closed-loop neurostimulation therapy for patients with moderate to severe obstructive sleep apnea (OSA) who cannot tolerate CPAP. The company sells primarily to hospitals and ambulatory surgery centers in the U.S. (95.6% of revenue) and select international markets.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $912.0 | $802.8 | +13.6% |
| Gross Profit | $778.8 | $679.8 | +14.6% |
| Gross Margin | 85.4% | 84.7% | +70 bps |
| Operating Income | $51.0 | $36.1 | +41.2% |
| Net Income | $145.4 | $53.5 | +171.8% |
| Diluted EPS | $4.89 | $1.75 | +179.4% |
| Cash & Investments | $404.6 | $516.5 | -$111.9 |
| Operating Cash Flow | $117.0 | $130.2 | -$13.2 |
Liquidity & Capital: As of December 31, 2025, the company held $404.6 million in cash, cash equivalents, and available-for-sale debt securities. Working capital totaled $487.6 million. The company has no long-term debt.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a $101.0 million increase in U.S. sales and $8.1 million in international sales. Growth was attributed to increased market penetration and awareness, partially offset by ENT surgeon capacity constraints and some patients delaying treatment to trial GLP-1 medications or await Inspire V availability.
- Profitability Surge: Net income more than doubled to $145.4 million. This was significantly boosted by a one-time deferred tax benefit of $88.8 million resulting from the release of the valuation allowance against net deferred tax assets, following three years of cumulative taxable income.
- Expense Trends:
- R&D: Decreased 9.6% to $103.2 million due to reduced costs for next-generation product development, partially offset by higher compensation.
- SG&A: Increased 17.9% to $624.6 million, driven by a $51.1 million increase in compensation (headcount growth) and a $33.0 million increase in marketing costs.
- Product Mix: Gross margin improved due to a higher sales mix of the Inspire V system, which has a lower cost of goods sold than the Inspire IV system.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary & Outlook
Management expects SG&A and R&D expenses to increase in 2026 to support commercial expansion and the development of the SleepSync platform and next-generation products. The company anticipates that GLP-1 weight-loss drugs may eventually expand the eligible patient pool for Inspire therapy by reducing BMI, though some patients may delay Inspire treatment to trial these drugs first.
Unusual Items
- Tax Benefit: The $88.8 million deferred tax benefit is a non-recurring item significantly impacting 2025 net income.
- Inventory Charge: A $2.1 million charge was recorded for excess component parts related to the Inspire IV system.
- Investment Impairment: A $4.0 million impairment charge was recognized on a strategic investment.
Risks and Contingencies
- Reimbursement Uncertainty: Confusion persists regarding the appropriate CPT coding for the Inspire V procedure (transitioning from 64568 to 64582 with a -52 modifier). The -52 modifier could reduce professional fees by 10-50%, potentially impacting physician willingness to perform the procedure.
- Legal Proceedings:
- Securities Litigation: A putative securities class action (Indiana PRS Lawsuit) alleges false statements regarding the Inspire V launch. A prior similar suit (City of Pontiac) was voluntarily dismissed.
- Government Investigation: The DOJ issued a Civil Investigative Demand (CID) regarding potential False Claims Act violations related to marketing and reimbursement practices.
- IP Litigation: Ongoing patent disputes with competitor Nyxoah, including lawsuits filed by both parties in the U.S. and the Unified Patent Court in Munich.
- Competition: Emerging competition from GLP-1 drugs (e.g., Zepbound) approved for OSA treatment and new neurostimulation devices from Nyxoah and LivaNova.
Key Facts for Investor Verification
- Tax Benefit Sustainability: Verify the sustainability of net income growth given the $88.8 million one-time tax benefit; future tax rates will likely be higher as the valuation allowance is released.
- Reimbursement Coding: Monitor the resolution of CPT coding confusion for Inspire V and the potential impact of the -52 modifier on physician reimbursement and procedure volumes.
- Legal Exposure: Track the status of the DOJ investigation and the Indiana PRS securities class action for potential financial liabilities or reputational damage.
- GLP-1 Impact: Assess the long-term net effect of GLP-1 drugs on Inspire demand (delayed treatment vs. expanded eligible patient pool).
- Share Repurchases: Note the company repurchased $175.0 million of stock in 2025, with $100.0 million remaining under the 2025 program.